此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

加强皮肤科护理,以减少采用阿米万他单抗加 Lazertinib 一线治疗的表皮生长因子受体 (EGRF) 突变的非小细胞肺癌 (NSCLC) 的皮疹和甲沟炎 (COCOON)

2026年11月2日 更新者:Janssen Research & Development, LLC

一项 2 期、开放标签、随机试验,评估强化与标准皮肤病管理对接受阿米万他单抗 + Lazertinib 一线治疗的局部晚期或转移性 EGFR 突变 NSCLC 患者中特定皮肤不良事件的影响

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.

研究概览

研究类型

介入性

注册 (实际的)

305

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Changzhou、中国、213004
        • Changzhou No 2 Peoples Hospital
      • Chengdoucun、中国、610041
        • West China Hospital
      • Chengdu、中国、610041
        • Sichuan Cancer Hospital
      • Guangzhou、中国、510080
        • The First Affiliated Hospital Sun Yat sen University
      • Hangzhou、中国、310003
        • The First Affiliated Hospital Zhejiang University School of Medicine
      • Harbin、中国、150040
        • Harbin medical university cancer hospital
      • Huizhou、中国、516001
        • Huizhou Municipal Central Hospital
      • Nanjing、中国、210000
        • Zhongda Hospital Southeast University
      • Shanghai、中国、200032
        • Fudan University Shanghai Cancer Center
      • Xi'an、中国、710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Zhengzhou、中国、450008
        • Henan Cancer Hospital
      • Hsinchu、台湾、30059
        • National Taiwan University Hospital Hsin Chu Branch
      • Kaohsiung City、台湾、833
        • Chang Gung Memorial Hospital
      • Taichung、台湾、40705
        • Taichung Veterans General Hospital
      • Taipei、台湾、100
        • National Taiwan University Hospital
      • Taoyuan City、台湾、333
        • Linkou Chang Gung Memorial Hospital
      • Adana、土耳其(türkiye)、1060
        • Adana City Hospital
      • Ankara、土耳其(türkiye)、06560
        • Gazi University Hospital
      • Ankara、土耳其(türkiye)、06010
        • Gulhane Training and Research Hospital
      • Ankara、土耳其(türkiye)、6800
        • Ankara Bilkent City Hospital
      • Istanbul、土耳其(türkiye)、34147
        • Bakirkoy Training and Research Hospital
      • Istanbul、土耳其(türkiye)、34295
        • I A U VM Medical Park Florya Hastanesi
      • Izmir、土耳其(türkiye)、35100
        • Ege University Medical Faculty
      • Samsun、土耳其(türkiye)、55420
        • Ondokuz Mayis University
      • Belo Horizonte、巴西、30150-221
        • Santa Casa de Misericordia de Belo Horizonte
      • Belém、巴西、66.073-005
        • CTO Centro De Tratamento Oncologico LTDA
      • Curitiba、巴西、81520-060
        • Liga Paranaense de Combate ao Cancer
      • Jaú、巴西、17.210-080
        • Fundacao Doutor Amaral Carvalho
      • Porto Alegre、巴西、91350 200
        • Hospital Nossa Senhora da Conceicao S A
      • Salvador、巴西、40170 070
        • Nucleo de Oncologia da Bahia Oncoclinicas
      • Santa Cruz do Sul、巴西、96835-100
        • Hospital Ana Nery Santa Cruz do Sul
      • São Paulo、巴西、01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo、巴西、01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • Taubaté、巴西、12030-200
        • Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate
      • Vitória、巴西、29043-260
        • Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
      • Aachen、德国、52074
        • Universitaetsklinikum der RWTH Aachen
      • Essen、德国、45136
        • Kliniken Essen-Mitte
      • Giessen、德国、35392
        • Universitaetsklinikum Giessen und Marburg GmbH
      • Heidelberg、德国、69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Kassel、德国、34125
        • Klinikum Kassel GmbH
      • Kiel、德国、24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Marseille、法国、13915
        • Hopital Nord
      • Nice、法国、06001
        • Hopital PASTEUR
      • Paris、法国、75005
        • Institut Curie
    • Arizona
      • Chandler、Arizona、美国、85224
        • Ironwood Cancer and Research Center
    • California
      • Duarte、California、美国、91010
        • City of Hope
      • Fullerton、California、美国、92835
        • Providence Fullerton
      • Glendale、California、美国、91204
        • Los Angeles Cancer Network
      • Huntington Beach、California、美国、92648
        • City of Hope Seacliff
      • Irvine、California、美国、92618
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Long Beach、California、美国、90813
        • City of Hope Long Beach Elm
      • Los Alamitos、California、美国、90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles、California、美国、90033
        • Keck Hospital of USC
      • Newport Beach、California、美国、92663
        • USC Norris Oncology Hematology Newport Beach
      • Oakland、California、美国、94611
        • Kaiser Permanente Oakland Medical Center
      • Roseville、California、美国、95661
        • Kaiser Permanente Roseville Medical Center
      • San Francisco、California、美国、94115
        • Kaiser Permanente San Francisco Medical Center
      • Santa Clara、California、美国、95051
        • Kaiser Permanente Santa Clara Medical Center
      • South Pasadena、California、美国、91030
        • City of Hope South Pasadena
      • Vallejo、California、美国、94589
        • Kaiser Permanente Northern California
      • Walnut Creek、California、美国、94596
        • Kaiser Permanente Walnut Creek Medical Center
    • Georgia
      • Athens、Georgia、美国、30607
        • University Cancer & Blood Center
    • Illinois
      • Hinsdale、Illinois、美国、60521
        • Hope and Healing Care
    • Missouri
      • Springfield、Missouri、美国、65807
        • Oncology Hematology Associates
    • Nevada
      • Reno、Nevada、美国、89502
        • Renown Health Medical Oncology
    • New Jersey
      • Flemington、New Jersey、美国、08822
        • Hunterdon Hematology Oncology
    • New York
      • Westbury、New York、美国、11590
        • Clinical Research Alliance Inc
    • North Carolina
      • Wilson、North Carolina、美国、27893
        • Regional Medical Oncology Center
    • Ohio
      • Cleveland、Ohio、美国、44106
        • University Hospitals Cleveland Medical Center
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Virginia Cancer Specialists
    • Washington
      • Renton、Washington、美国、98055
        • Valley Medical Center
    • Wisconsin
      • West Salem、Wisconsin、美国、54669
        • Gundersen Health System
      • A Coruña、西班牙、15006
        • Hosp Univ A Coruna
      • Alicante、西班牙、03010
        • Hosp. Gral. Univ. de Alicante
      • Barcelona、西班牙、08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona、西班牙、08035
        • Hosp Univ Vall D Hebron
      • Jaén、西班牙、23007
        • Hosp. Univ. de Jaen
      • Lugo、西班牙、27003
        • Hosp. Univ. Lucus Augusti
      • Madrid、西班牙、28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Málaga、西班牙、29010
        • Hosp Regional Univ de Malaga
      • Seville、西班牙、41014
        • Hosp. Ntra. Sra. de Valme
      • Buenos Aires、阿根廷、C1199
        • Hospital Italiano de Buenos Aires
      • CABA、阿根廷、C1122
        • IADT Instituto Argentino de Diagnostico y Tratamiento
      • Capital Federal、阿根廷、C1017
        • Centro Medico Austral
      • La Plata、阿根廷、B1900AXI
        • Hospital Italiano de La Plata
      • Mar del Plata、阿根廷、B7602
        • Hospital Privado de la Comunidad
      • Cheongju-si、韩国、28644
        • Chungbuk National University Hospital
      • Incheon、韩国、21565
        • Gachon University Gil Medical Center
      • Seoul、韩国、03722
        • Severance Hospital Yonsei University Health System
      • George Town、马来西亚、10450
        • Hospital Pulau Pinang
      • Kuala Lumpur、马来西亚、59100
        • University Malaya Medical Centre
      • Kuantan、马来西亚、25100
        • Hospital Tengku Ampuan Afzan
      • Kuching、马来西亚、93586
        • Hospital Umum Sarawak

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease
  • Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care
  • A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease
  • Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohorts: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded
  • Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care [SoC]) Grade >=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)

Exclusion Criteria:

  • History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohorts, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator
  • Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
  • Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol*, ruxolitinib*, zinc*, corticosteroids* or their excipients or to any component of the enhanced dermatologic management (*for the amivantamab SC expansion cohorts)
  • Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Sub-study: Participants who have received prior treatment for epidermal growth factor receptor (EGFR)-induced DAEIs with JAK inhibitors (for Cohort A) or calcineurin inhibitors (for Cohort B)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A: Enhanced Dermatologic Management

Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously (Dose 1 for body weight [BW] less than 80 kilograms [kg] and Dose 2 for BW greater than or equal to [>=] 80 kg as IV infusion [Arm A]) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1).

Amivantamab will be administered.

其他名称:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

其他名称:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

有源比较器:Arm B: Standard-of-Care Dermatologic Management

Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm.

Amivantamab will be administered.

其他名称:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

其他名称:
  • JNJ-73841937

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

实验性的:Sub-study: Cohort A: Ruxolitinib

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to [>=] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

其他名称:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

其他名称:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

实验性的:Sub-study: Cohort B: Tacrolimus

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade >= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

其他名称:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

其他名称:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Tacrolimus will be used as topical application to the affected skin area.

实验性的:Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

其他名称:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

Amivantamab will be administered as SC injection.

其他名称:
  • JNJ-61186372

Zinc gluconate tablet will be administered.

Propranolol tablet will be administered.

Timolol will be used to the affected skin area.

Clobetasol shampoo will be used on the scalp.

实验性的:Amivantamab SC Expansion Cohort: Modified Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

其他名称:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Amivantamab will be administered as SC injection.

其他名称:
  • JNJ-61186372

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
大体时间:Up to 12 weeks after initiation of anticancer treatment

Number of participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment

次要结果测量

结果测量
措施说明
大体时间
Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0
大体时间:Up to 12 weeks after initiation of anticancer treatment

Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 weeks after initiation of anticancer treatment
Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0
大体时间:Up to 6 months after initiation of anticancer treatment

Number of participants with Grade >=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Grade >= 2 DAEI Per Participants
大体时间:Up to 12 months

Number of grade >= 2 DAEI per participants will be reported.

Up to 12 months
Time to First Occurrence of Grade >=2 DAEI
大体时间:Up to 12 months

Time to first occurrence of Grade >=2 DAEI will be reported.

Up to 12 months
Time to Resolution of Grade >= 2 DAEI
大体时间:Up to 12 months

Time to resolution of Grade >= 2 DAEI will be reported.

Up to 12 months
Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0
大体时间:Up to 6 months after initiation of anticancer treatment

Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0
大体时间:Up to 12 months after initiation of anticancer treatment

Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 months after initiation of anticancer treatment
Change From Baseline in Skindex Symptoms Domain Score up to 12 Months
大体时间:Baseline, up to Month 12

Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions.

Baseline, up to Month 12
Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months
大体时间:Baseline, up to Month 12

Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale.

Baseline, up to Month 12
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months
大体时间:Baseline, up to Month 12

Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline, up to Month 12
Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only)
大体时间:Baseline, up to Month 12

The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 [no limitation] to 4 [incapacity]).

Baseline, up to Month 12
Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs
大体时间:Up to 12 months

Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported.

Up to 12 months
Relative Dose Intensity (RDI) of Anticancer Treatment
大体时间:Up to 12 months

Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose.

Up to 12 months
Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
大体时间:Up to 12 months

Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
大体时间:Up to 12 months

Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Progression Free Survival (PFS)
大体时间:Up to 12 months

PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first.

Up to 12 months
Overall Response Rate (ORR)
大体时间:Up to 12 months

ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator.

Up to 12 months
Duration of Response (DoR)
大体时间:Up to 12 months

DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria.

Up to 12 months
Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment
大体时间:Up to 12 weeks after initiation of anticancer treatment

Participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment
Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention
大体时间:Up to 12 months

Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months
Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention
大体时间:Up to 12 months

Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months

其他结果措施

结果测量
措施说明
大体时间
Percentage of Participants Achieving Best Response for the Dermatologic Adverse Event
大体时间:Up to 12 weeks

Participants achieving best response within 12 weeks of treatment defined as NCI-CTCAE level of the dermatologic adverse event improvement by at least 1 level will be reported.

Up to 12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年2月16日

初级完成 (估计的)

2027年5月31日

研究完成 (估计的)

2030年6月30日

研究注册日期

首次提交

2023年11月2日

首先提交符合 QC 标准的

2023年11月2日

首次发布 (实际的)

2023年11月7日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅